{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:02:46Z","timestamp":1790614966139,"version":"4.1.0"},"reference-count":200,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>With the rapid introduction of novel breast cancer therapies, recognizing and managing side effects is essential to maintain adherence and improve outcomes. As novel oral endocrine therapies and combination strategies including targeted agents have prolonged progression and in some cases disease-free survival, early recognition and appropriate management of these toxicities is critical to optimize quality of life. Dermatologic adverse events are frequently associated with novel breast cancer therapies including immune checkpoint inhibitors (ICIs), targeted therapies, and antibody-drug conjugates (ADCs). These include various rashes, stomatitis, and alopecia, necessitating multidisciplinary dermatologic intervention to allow for prompt management of cutaneous toxicities and continuation of oncologic therapy. Targeted breast cancer therapies, including ADCs, can also induce ocular adverse events (OAEs), such as corneal pseudomicrocysts which lead to blurry vision and eye pain. Current preventative therapies have had limited success for these OAEs, necessitating dose interruptions. Although anthracycline-based chemotherapy and human epidermal growth factor receptor 2 (HER2)\u2013targeted therapy are associated with an increased risk of heart failure and left ventricular (LV) dysfunction, novel breast cancer therapies including ADCs, HER2 tyrosine kinase inhibitors, cyclin-dependent kinase 4 and 6 inhibitors, ICIs, and oral selective estrogen receptor degrader are also associated with an increased risk of LV dysfunction, heart failure, corrected QT prolongation, myocarditis, and bradycardia. This review provides a comprehensive overview of novel and emerging breast cancer therapy toxicities, with suggested management strategies to prevent and mitigate these adverse events. Through a multidisciplinary approach involving preventative strategies, monitoring, proactive interventions, providers can minimize symptom burden and improve patient adherence, ultimately improving breast cancer outcomes.<\/jats:p>","DOI":"10.1200\/edbk-25-473384","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T19:59:08Z","timestamp":1752091148000},"source":"Crossref","is-referenced-by-count":8,"title":["New Drugs, New Toxicities: Side Effects of New and Emerging Breast Cancer Therapies"],"prefix":"10.1200","volume":"45","author":[{"given":"Alexis","family":"LeVee","sequence":"first","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alana","family":"Deutsh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan S.","family":"Lindgren","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongshan","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Moore","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Duke University Medical Center, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel D.","family":"Pasricha","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Leventhal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dent","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6710-4814","authenticated-orcid":true,"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198902233200802"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.21.1529"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199811263392207"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm263"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3613-z"},{"key":"e_1_3_3_7_2","unstructured":"Shapiro CL: Bone-modifying Agents (BMAs) in Breast Cancer. (1938-0666 (Electronic))"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044750"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11113133"},{"key":"e_1_3_3_10_2","volume-title":"Tamoxifen [package insert]","author":"Golden State Medical Supply I. U.S. Food & Drug Administration","year":"2024","unstructured":"Golden State Medical Supply I. U.S. Food & Drug Administration: Tamoxifen [package insert]. 2024"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S1566"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-011-1351-3"},{"key":"e_1_3_3_13_2","unstructured":"Aurobindo Pharma L. U.S. Food & Drug Administration: Letrozole"},{"key":"e_1_3_3_14_2","unstructured":"Pd-Rx Pharmaceuticals I. U.S. Food & Drug Administration: Anastrozole"},{"key":"e_1_3_3_15_2","unstructured":"Upsher-Smith Laboratories I. U.S. Food & Drug Administration: Exemestane"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32389-3"},{"key":"e_1_3_3_17_2","unstructured":"Accord Healthcare I. U.S. Food & Drug Administration: Fulvestrant"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00338"},{"key":"e_1_3_3_19_2","unstructured":"Stemline Therapeutics I. U.S. Food & Drug Administration: Orserdu"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607303"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810527"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00137"},{"key":"e_1_3_3_23_2","unstructured":"Pfizer Laboratories Div Pfizer I. U.S. Food & Drug Administration: Ibrance"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609709"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2305488"},{"key":"e_1_3_3_26_2","unstructured":"Novartis Pharmaceuticals C. U.S. Food & Drug Administration: Kisqali"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903765"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911149"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.4782"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00694-5"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.04.013"},{"key":"e_1_3_3_32_2","unstructured":"Eli L Company. U.S. Food & Drug Administration: Verzenio"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109653"},{"key":"e_1_3_3_34_2","unstructured":"Teva Pharmaceuticals USA I. U.S. Food & Drug Administration: Everolimus"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1813904"},{"key":"e_1_3_3_36_2","unstructured":"Novartis Pharmaceuticals C. U.S. Food & Drug Administration: Piqray"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214131"},{"key":"e_1_3_3_38_2","unstructured":"AstraZeneca Pharmaceuticals LP. U.S. Food & Drug Administration: Truqap"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404625"},{"key":"e_1_3_3_40_2","unstructured":"Genentech I. U.S. Food & Drug Administration: Itovebi"},{"key":"e_1_3_3_41_2","first-page":"123","article-title":"Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions","volume":"2","author":"Pachman DR","year":"2010","unstructured":"Pachman DR, Jones JM, Loprinzi CL: Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions. Int J Womens Health 2:123-135, 2010","journal-title":"Int J Womens Health"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz088"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00085-5"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.18.00710"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2010-0435"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3904"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3878-2"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3960-9"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2023.08.003"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102880"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.8525"},{"key":"e_1_3_3_52_2","doi-asserted-by":"publisher","DOI":"10.1080\/0092623X.2017.1408047"},{"key":"e_1_3_3_53_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-019-00800-x"},{"key":"e_1_3_3_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103754"},{"key":"e_1_3_3_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-024-01633-3"},{"key":"e_1_3_3_56_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl304"},{"key":"e_1_3_3_57_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.12015"},{"key":"e_1_3_3_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000003500"},{"key":"e_1_3_3_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11227"},{"key":"e_1_3_3_60_2","doi-asserted-by":"publisher","DOI":"10.1177\/1534735411413270"},{"key":"e_1_3_3_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/ecc.12155"},{"key":"e_1_3_3_62_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0174"},{"key":"e_1_3_3_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32051"},{"key":"e_1_3_3_64_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-94466-0"},{"key":"e_1_3_3_65_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.8907"},{"key":"e_1_3_3_66_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4708"},{"key":"e_1_3_3_67_2","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.00113"},{"key":"e_1_3_3_68_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.6651"},{"key":"e_1_3_3_69_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-009-0692-7"},{"key":"e_1_3_3_70_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0261"},{"key":"e_1_3_3_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60908-4"},{"key":"e_1_3_3_72_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6155"},{"key":"e_1_3_3_73_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02514"},{"key":"e_1_3_3_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01415-9"},{"key":"e_1_3_3_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.03.006"},{"key":"e_1_3_3_76_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy109"},{"key":"e_1_3_3_77_2","unstructured":"Kuo AM Reingold RE Ketosugbo KF et al: Oral Minoxidil for Late Alopecia in Cancer Survivors. (1573-7217 (Electronic))"},{"key":"e_1_3_3_78_2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2020.1853228"},{"key":"e_1_3_3_79_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211027931"},{"key":"e_1_3_3_80_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1256783"},{"key":"e_1_3_3_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101098"},{"key":"e_1_3_3_82_2","doi-asserted-by":"publisher","DOI":"10.1080\/1120009X.2024.2433368"},{"key":"e_1_3_3_83_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e13067"},{"key":"e_1_3_3_84_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.7356"},{"key":"e_1_3_3_85_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.665647"},{"key":"e_1_3_3_86_2","doi-asserted-by":"crossref","unstructured":"Rugo HS Chan SMTN Hamilton E et al: Elacestrant plus abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+) HER2-negative (HER2-) advanced or metastatic breast cancer (mBC). presented at: San Antonio Breast Cancer Symposium (SABCS) 2024","DOI":"10.1158\/1557-3265.SABCS24-PS7-07"},{"key":"e_1_3_3_87_2","doi-asserted-by":"crossref","unstructured":"Rugo HS Tolaney SM Chan N et al: Elacestrant combinations in patients with estrogen receptor-positive (ER+) HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Update from ELEVATE a phase 1b\/2 open-label umbrella study. presented at: San Antonio Breast Cancer Symposium (SABCS) 2024","DOI":"10.1200\/JCO.2024.42.16_suppl.1069"},{"key":"e_1_3_3_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30109-2"},{"key":"e_1_3_3_89_2","unstructured":"Rugo HS Pritchard KI Gnant M et al: Incidence and Time Course of Everolimus-Related Adverse Events in Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer: Insights from BOLERO-2. pp 1569-8041. (Electronic)"},{"key":"e_1_3_3_90_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS19-OT1-08-04"},{"key":"e_1_3_3_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102520"},{"key":"e_1_3_3_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.001"},{"key":"e_1_3_3_93_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz440"},{"key":"e_1_3_3_94_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030619"},{"key":"e_1_3_3_95_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-1236"},{"key":"e_1_3_3_96_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7585"},{"key":"e_1_3_3_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00387-5"},{"key":"e_1_3_3_98_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01500"},{"key":"e_1_3_3_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101394"},{"key":"e_1_3_3_100_2","unstructured":"Arvinas. Press Release: Arvinas and Pfizer announce positive topline results from phase 3 VERITAC-2 clinical trial. 2025"},{"key":"e_1_3_3_101_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.559"},{"key":"e_1_3_3_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3104"},{"key":"e_1_3_3_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3103"},{"key":"e_1_3_3_104_2","first-page":"331","article-title":"Management of dermatologic toxicities associated with targeted therapy","volume":"7","author":"Lacouture ME","year":"2016","unstructured":"Lacouture ME: Management of dermatologic toxicities associated with targeted therapy. J Adv Pract Oncol 7:331-334, 2016","journal-title":"J Adv Pract Oncol"},{"key":"e_1_3_3_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijwd.2019.10.003"},{"key":"e_1_3_3_106_2","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2016.2833"},{"key":"e_1_3_3_107_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70488-3"},{"key":"e_1_3_3_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132"},{"key":"e_1_3_3_109_2","first-page":"SF389716s3","article-title":"Individual article: USCOM algorithm for the prevention and management of cutaneous immunotherapy-related adverse events","volume":"22","author":"Deutsch A","year":"2023","unstructured":"Deutsch A, Lacouture M, Andriessen A, et al: Individual article: USCOM algorithm for the prevention and management of cutaneous immunotherapy-related adverse events. J Drugs Dermatol 22:SF389716s3-SF389716s10, 2023","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_110_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.09.054"},{"key":"e_1_3_3_111_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440"},{"key":"e_1_3_3_112_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-020-05726-y"},{"key":"e_1_3_3_113_2","doi-asserted-by":"publisher","DOI":"10.36401\/JIPO-20-16"},{"key":"e_1_3_3_114_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100596"},{"key":"e_1_3_3_115_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.726785"},{"key":"e_1_3_3_116_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706450"},{"key":"e_1_3_3_117_2","first-page":"9529821","article-title":"A novel adverse event associated with olaparib therapy in a patient with metastatic breast cancer","volume":"2018","author":"Wheelden M","year":"2018","unstructured":"Wheelden M, Cream L, Sivik J, et al: A novel adverse event associated with olaparib therapy in a patient with metastatic breast cancer. Case Rep Oncol Med 2018:9529821, 2018","journal-title":"Case Rep Oncol Med"},{"key":"e_1_3_3_118_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2023.07.011"},{"key":"e_1_3_3_119_2","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-249177"},{"key":"e_1_3_3_120_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1810168"},{"key":"e_1_3_3_121_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101162"},{"key":"e_1_3_3_122_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03107"},{"key":"e_1_3_3_123_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30786-1"},{"key":"e_1_3_3_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.09.002"},{"key":"e_1_3_3_125_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.08.036"},{"key":"e_1_3_3_126_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03266-2"},{"key":"e_1_3_3_127_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102720"},{"key":"e_1_3_3_128_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914510"},{"key":"e_1_3_3_129_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203690"},{"key":"e_1_3_3_130_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2407086"},{"key":"e_1_3_3_131_2","doi-asserted-by":"publisher","DOI":"10.3233\/BD-220052"},{"key":"e_1_3_3_132_2","volume-title":"Enhertu. Prescribing Information","author":"Daiichi Sankyo I","year":"2025","unstructured":"Daiichi Sankyo I: Enhertu. Prescribing Information. 2025"},{"key":"e_1_3_3_133_2","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2023-0041"},{"key":"e_1_3_3_134_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2022.3026"},{"key":"e_1_3_3_135_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40135-024-00322-5"},{"key":"e_1_3_3_136_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01035-z"},{"key":"e_1_3_3_137_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70178-0"},{"key":"e_1_3_3_138_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.9777"},{"key":"e_1_3_3_139_2","doi-asserted-by":"publisher","DOI":"10.3390\/genes13112065"},{"key":"e_1_3_3_140_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03398"},{"key":"e_1_3_3_141_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_3_142_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01245-X"},{"key":"e_1_3_3_143_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00920"},{"key":"e_1_3_3_144_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.1075"},{"key":"e_1_3_3_145_2","unstructured":"Highlights of prescribing information these highlights do not include all the information needed to use KADCYLA safely and effectively. See full prescribing information for KADCYLA. KADCYLA\u2122 (ado-trastuzumab emtansine) for injection for intravenous use initial U.S. Approval: YYYY. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125427lbl.pdf"},{"key":"e_1_3_3_146_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00529"},{"key":"e_1_3_3_147_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02149-3"},{"key":"e_1_3_3_148_2","article-title":"Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC)","volume":"42","author":"Ye D-W","year":"2024","unstructured":"Ye D-W, Zhang J, Yang H, et al: Phase 1 dose escalation of SYS6002 (CRB-701), a next-generation nectin-4 targeting antibody drug conjugate (ADC). J Clin Oncol 42, 2024 (suppl 4; abstr 622)","journal-title":"J Clin Oncol"},{"key":"e_1_3_3_149_2","doi-asserted-by":"publisher","DOI":"10.1080\/15569527.2024.2408677"},{"key":"e_1_3_3_150_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2015.0064"},{"key":"e_1_3_3_151_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002595"},{"key":"e_1_3_3_152_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002934"},{"key":"e_1_3_3_153_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-020-00280-8"},{"key":"e_1_3_3_154_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01172-5"},{"key":"e_1_3_3_155_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2021.101133"},{"key":"e_1_3_3_156_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.07.047"},{"key":"e_1_3_3_157_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0196-6"},{"key":"e_1_3_3_158_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000768"},{"key":"e_1_3_3_159_2","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox202"},{"key":"e_1_3_3_160_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2023.101155"},{"key":"e_1_3_3_161_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2023.0069"},{"key":"e_1_3_3_162_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_3_163_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2474"},{"key":"e_1_3_3_164_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000001805"},{"key":"e_1_3_3_165_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678634"},{"key":"e_1_3_3_166_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2022.02.010"},{"key":"e_1_3_3_167_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.03.005"},{"key":"e_1_3_3_168_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2022.0006"},{"key":"e_1_3_3_169_2","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-2591"},{"key":"e_1_3_3_170_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2024.0019"},{"key":"e_1_3_3_171_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-3202"},{"key":"e_1_3_3_172_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285821"},{"key":"e_1_3_3_173_2","doi-asserted-by":"publisher","DOI":"10.4172\/2155-9880.1000507"},{"key":"e_1_3_3_174_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.0868"},{"key":"e_1_3_3_175_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910383"},{"key":"e_1_3_3_176_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703643"},{"key":"e_1_3_3_177_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjco.2021.06.019"},{"key":"e_1_3_3_178_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022"},{"key":"e_1_3_3_179_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03261-7"},{"key":"e_1_3_3_180_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209124"},{"key":"e_1_3_3_181_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01114-x"},{"key":"e_1_3_3_182_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30717-9"},{"key":"e_1_3_3_183_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00147"},{"key":"e_1_3_3_184_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914609"},{"key":"e_1_3_3_185_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0753"},{"key":"e_1_3_3_186_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3032"},{"key":"e_1_3_3_187_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"e_1_3_3_188_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32531-9"},{"key":"e_1_3_3_189_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910549"},{"key":"e_1_3_3_190_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03414-8"},{"key":"e_1_3_3_191_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03415-7"},{"key":"e_1_3_3_192_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176424"},{"key":"e_1_3_3_193_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.30.3909"},{"key":"e_1_3_3_194_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.4"},{"key":"e_1_3_3_195_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29088"},{"key":"e_1_3_3_196_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.0830"},{"key":"e_1_3_3_197_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.03.004"},{"key":"e_1_3_3_198_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2020.01.004"},{"key":"e_1_3_3_199_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11764-020-00942-3"},{"key":"e_1_3_3_200_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.05.003"},{"key":"e_1_3_3_201_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102236"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-25-473384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T19:59:15Z","timestamp":1752091155000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-25-473384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":200,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/EDBK-25-473384"],"URL":"https:\/\/doi.org\/10.1200\/edbk-25-473384","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"article-number":"e473384"}}